Kerry Weems, a finance and budget expert, formerly the chief of CMS, warns managed care of rate fights around every corner.
Nominated for the position of administrator of the Centers for Medicare & Medicaid Services (CMS) by the president in 2007, Kerry Weems, a finance and budget expert, was never officially confirmed. Even so, as acting administrator for more than a year, Weems launched e-prescribing programs, electronic health record pilots, the nursing home quality-comparison Web site, and the CMS do-not-pay list for egregious medical errors.
The confirmation process for such an official typically includes some partisan wrangling on the Senate floor. With a long list of sensitive healthcare issues under examination-including the debate over the expansion of the State Children's Health Insurance Program (SCHIP) in the summer of 2007-Democratic senators were unwilling to confirm a top healthcare leader nominated by the Bush administration.
Weems was a respected official who was adept at keeping Medicare and Medicaid running efficiently. Not being confirmed was a limiting factor in promoting controversial programs and policies, but he did follow through on the promise he made in his nomination testimony to intensify CMS oversight. He was particularly driven to wring fraudulent activities out of the Medicare and Medicaid payment system.
Now retired from government, Weems continues to influence healthcare's evolution as the senior vice president and general manager for health solutions with global consulting firm Vangent Inc. He remains an advocate of interoperable health records, fraud prevention, comparative effectiveness, value-based purchasing and quality reporting.
"When you leave government after 28 years, you have these notions of what you might want to do," he says. "It really took an entire six or seven month period for me to shed my government skin and decide what I wanted was to work in a health practice and continue moving healthcare in America along to higher quality and lower cost."
The major policy issues haven't changed much since Weems left government. He recently sat down with MHE to assess a few of the industry's biggest challenges.
AI Benefits PBMs, Health Plans and Formulary Decision Making | AMCP Nexus 2024
October 21st 2024Health plans and PBMs are using AI to aggregate data, summarize information and enhance their formulary decision-making processes, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
The Link between GLP-1 Drugs and Diabetic Retinopathy Is Not So Clear | AAO 2024
Published: October 21st 2024 | Updated: October 21st 2024Clinical and other trials for GLP-1 therapies have found an association between these drugs and diabetic retinopathy complications in patients. But this could be an early worsening of disease unrelated to treatment.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen